JP Morgan Maintains Overweight on Insmed, Raises Price Target to $72
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Jessica Fye maintains an Overweight rating on Insmed (NASDAQ:INSM) and raises the price target from $55 to $72.
June 20, 2024 | 1:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan analyst Jessica Fye maintains an Overweight rating on Insmed and raises the price target from $55 to $72.
The raised price target and maintained Overweight rating from a reputable analyst at JP Morgan is likely to positively impact Insmed's stock price in the short term. Investors often react favorably to such updates, especially when the price target is significantly increased.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100